Clinical Trial

Disease: Chronic Granulomatous Disease, (NCT06559176)

Disease info:

Chronic granulomatous disease (CGD) results in immune system dysfunction, leading to immunodeficiency. This may cause recurring bacterial and fungal infections and inflammation in various parts of the body. Symptoms usually start in childhood, though some may not appear until later in life.

Individuals with CGD often experience serious bacterial or fungal infections every few years, with the lungs being the most common site of infection, often leading to pneumonia. Exposure to certain organic materials can trigger fungal pneumonia. Other areas commonly affected include the skin, liver, and lymph nodes. In some cases, CGD can lead to autoimmune disorders, where the immune system mistakenly attacks the body's own tissues. Repeated infections and inflammation can shorten life expectancy, but with treatment, most people with CGD can live into their mid- to late adulthood.

Most cases of CGD are caused by mutations in five genes, CYBACYBBNCF1NCF2CYBC1, or NCF4, which each encode a subunit of the NADPH oxidase enzyme complex that plays a crucial role in immune function. CGD is categorised into five types, distinguished by the associated genetic variant. A mutation in the CYBB gene (Xp21.1) is found in approximately 65% of cases in North America and Western Europe. The resulting deficiency in the NADPH oxidase enzyme complex leads to decreased production of reactive oxygen species (used by phagocytes to kill bacteria and fungi). Consequently, individuals with CGD are prone to infections and excessive inflammation. Some cases of CGD have unknown genetic causes. 

CGD presents with a range of symptoms affecting various organ systems. Common manifestations include severe and recurrent infections, often caused by specific pathogens such as Staphylococcus aureus and Aspergillus spp. Additionally, patients may develop granulomatous lesions, primarily affecting the lungs, lymph nodes, gastrointestinal tract, and liver. Up to half of patients may experience symptoms such as diarrhoea, abdominal pain, and failure to thrive. Common complications can include pneumonia, abscesses, cellulitis, adenitis, and osteomyelitis. Mycobacterial diseases are typically limited to tuberculosis or disseminated Bacillus Calmette-Guérin (BCG) infections, while invasive fungal infections are frequent. Dysregulated inflammation and granuloma formation can lead to various complications, including chorioretinal lesions, gastric outlet obstruction, inflammatory bowel disease (IBD), and wound complications. Most female carriers of CGD show no symptoms unless a significant portion of their neutrophils are dysfunctional. Some individuals with CGD may develop autoimmune disorders such as discoid lupus erythematosus and antiphospholipid syndrome.

Frequency:
CGD is estimated to occur in 1 in 200,000 to 250,000 people worldwide.
Official title:
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Modified Ex Vivo Using Prime Editing (PM359) in Participants With Autosomal Recessive Chronic Granulomatous Disease Due to Mutations in the NCF1 Gene
Who:
Partners:
Locations:

United States, California 

Los Angeles, California, United States, 90027

University of California Los Angeles Medical Center

United States, Maryland

Bethesda, Maryland, United States, 20892

NIH Clinical Center

United States, Tennessee

Nashville, Tennessee, United States, 37203

The Children's Hospital at Tristar Medical Group/Sarah Cannon Center for Blood Cancers

Canada, Quebec 

Montréal, Quebec, Canada, H3T 1C5

CHU - Sainte Justine Hospital

United Kingdom, England

London, England, United Kingdom, NW1 2PG

University College of London Hospital

Study start:
Oct. 17, 2024
Enrollment:
12
Gene editing method:
Prime editing
Type of edit:
Gene correction
Gene:
NCF1 gene, which encodes the p47phox protein
Delivery method:
Electroporation - Ex-vivo
IndicatorIndicator
IND Enabling Pre-clinical
Phase I Safety
Phase II Safety and Dosing
Phase III Safety and Efficacy

Status: Active not recruiting

Description

This study seeks to understand the safety and efficacy of a new gene editing technology, known as Prime Editing, in participants with autosomal recessive CGD caused by the delGT mutation in NCF1. Autologous CD34+ cells are collected from the participant via mobilization and apheresis, shipped to a central manufacturing facility and modified using Prime Editing to 'correct' the delGT mutation causing p47phox CGD. After manufacture, the Prime Edited stem cells (PM359) will be shipped to the study site, where they will be infused back into the participant following a preparative procedure known as conditioning.

The study will initially enroll adult participants (aged ≥ 18) and plans to then move into adolescents aged 12 - 17, followed by children aged 6 - 11.

Last updated: Jun. 23, 2025
close
Search CRISPR Medicine